Table 1 Characteristics of AML patients (18–60 y) according to UBTF status.

From: UBTF tandem duplications define a distinct subtype of adult de novo acute myeloid leukemia

Parameters

UBTF-TD AML 18–60 y

UBTF wild-type AML 18–60 y (ALFA-0702)

No. of patients

57

593

Age (y), median (IQR)

36 (24–45)

47 (37–54)

WBC (×109/L), median (IQR)

3.55 (2–27.4)

8.3 (2.6–32.9)

BM blasts (%), median (IQR)

25 (20–63)

60 (39–82)

BM morphology, n (%)

  M0

0

28/467 (6%)

  M1/M2

15/33 (45%)

254/467 (54%)

  M4/M5

0

169/467 (36%)

  M6

14/33 (42%)

14/467 (3%)

  M7

0

2/467 (0%)

  MRC

4/33 (12%)

 

Cytogenetics

  Normal, n (%)

38/57 (67%)

329/563 (58%)

  Trisomy 8, n (%)

16/57 (28%)

46/545 (8%)

  Monosomy 5/del(5q), n (%)

0

33/545 (6%)

  Monosomy 7/del(7q), n (%)

0

47/545 (9%)

  Monosomy 17/del(17p), n (%)

0

22/545 (4%)

  Del(20q), n (%)

0

14/545 (3%)

  Del(12p), n (%)

0

14/545 (3%)

  Complex, n (%)

0

67/545 (12%)

 WT1 mutations, n (%)

36/57 (63%)

48/572 (8%)

Signaling mutations

  FLT3-ITD, n (%)

30/57 (53%)

127/572 (22%)

  FLT3-TKD, n (%)

4/57 (7%)

72/572 (13%)

  NRAS, n (%)

13/57 (23%)

126/572 (22%)

  KRAS, n (%)

7/57 (12%)

43/572 (8%)

  PTPN11, n (%)

6/57 (11%)

32/572 (6%)

  RIT1, n (%)

6/57 (11%)

19/572 (3%)

DNA-methylation gene mutations

  DNMT3A, n (%)

3/57 (5%)

162/572 (28%)

  TET2, n (%)

5/57 (9%)

74/572 (13%)

  IDH1, n (%)

3/57 (5%)

53/572 (9%)

  IDH2, n (%)

3/57 (5%)

74/572 (13%)

NPM1 mutations, n (%)

0

208/572 (36%)

CEBPA double mutations, n (%)

0

30/572 (5%)

TP53 mutations, n (%)

0

39/572 (7%)

MDS-related gene mutations*, n (%)

5/57 (9%)

168/572 (29%)

ELN 2022 risk

  Favorable

0

143/548 (26%)

  Intermediate

52/57 (91%)

157/548 (29%)

  Adverse

5/57 (9%)

248/548 (45%)

  1. *MDS-related genes: ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2.
  2. These data refer to only 57 of the 59 patients with UBTF-TDs (the 2 patients over 60 years of age were excluded for comparisons).
  3. BM bone marrow, IQR interquartile range, MRC myelodysplastic-related changes, WBC white blood cell count.